ArticlePloS one2026
Topical medium-length PDRN enhances dermal extracellular matrix repair in photodamaged skin via PI3K-Akt/TGF-β-regulated pathways.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic ultraviolet (UV) exposure disrupts dermal fibroblast function and extracellular matrix (ECM) homeostasis, driving the structural features of photoaged skin. Polydeoxyribonucleotide (PDRN) has shown regenerative effects in injectable applications, but the mechanism and delivery of topical PDRN remain insufficiently defined. This study investigated the mechanism, skin delivery, and efficacy of a medium-length PDRN preparation (PDRN-850K) in photodamaged skin. Pathway activation was examined in basal human dermal fibroblasts using western blotting, gene expression analysis, and pharmacological inhibition. Skin delivery was assessed by confocal Raman spectroscopy in a reconstructed epidermal model and by complementary ex vivo and in vivo penetration studies. Tissue-level effects were assessed in a UV-irradiated human ex vivo skin model. Clinical efficacy was evaluated in a randomized, double-blind, split-face study comparing 0.1% PDRN-850K eye cream with 0.1% retinol over 28 days. PDRN-850K activated PI3K-Akt, TGF-β/Smad, and autophagy-related signaling in basal fibroblasts, and inhibition of these pathways reduced ECM gene induction. Raman analysis demonstrated time-dependent distribution of PDRN-associated signal into viable epidermal regions, with additional support from FITC-labeled porcine skin and pilot in vivo human Raman studies. In UV-irradiated ex vivo skin, PDRN-850K increased viable epidermal thickness and upregulated multiple collagens, elastic fiber-associated proteins, and YAP. Clinically, PDRN-850K achieved approximately two-fold greater improvements in periocular wrinkles, dermal thickness, density, and eye bag parameters compared with retinol, with good tolerability. These findings support PDRN-850K as a topical pro-repair approach for photodamaged skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.